PURPOSE: Deletions of chromosome 1 have been described in 7% to 40% of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. We tested the clinical impact of 1p deletion and used high-resolution techniques to define the role of CDKN2C in primary patient material. EXPERIMENTAL DESIGN: We analyzed 515 cases of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma using fluorescence in situ hybridization (FISH) for deletions of CDKN2C. In 78 myeloma cases, we carried out Affymetrix single nucleotide polymorphism mapping and U133 Plus 2.0 expression arrays. In addition, we did mutation, methylation, and Western blotting analysis. RESULTS: By FISH we identified deletion of 1p32.3 (CDKN2C) in 3 of 66 MGUS (4.5%), 4 of 39 SMM (10.3%), and 55 of 369 multiple myeloma cases (15%). We examined the impact of copy number change at CDKN2C on overall survival (OS), and found that the cases with either hemizygous or homozygous deletion of CDKN2C had a worse OS compared with cases that were intact at this region (22 months versus 38 months; P = 0.003). Using gene mapping we identified three homozygous deletions at 1p32.3, containing CDKN2C, all of which lacked expression of CDKN2C. Cases with homozygous deletions of CDKN2C were the most proliferative myelomas, defined by an expression-based proliferation index, consistent with its biological function as a cyclin-dependent kinase inhibitor. CONCLUSIONS: Our results suggest that deletions of CDKN2C are important in the progression and clinical outcome of myeloma.
PURPOSE: Deletions of chromosome 1 have been described in 7% to 40% of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. We tested the clinical impact of 1p deletion and used high-resolution techniques to define the role of CDKN2C in primary patient material. EXPERIMENTAL DESIGN: We analyzed 515 cases of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma using fluorescence in situ hybridization (FISH) for deletions of CDKN2C. In 78 myeloma cases, we carried out Affymetrix single nucleotide polymorphism mapping and U133 Plus 2.0 expression arrays. In addition, we did mutation, methylation, and Western blotting analysis. RESULTS: By FISH we identified deletion of 1p32.3 (CDKN2C) in 3 of 66 MGUS (4.5%), 4 of 39 SMM (10.3%), and 55 of 369 multiple myeloma cases (15%). We examined the impact of copy number change at CDKN2C on overall survival (OS), and found that the cases with either hemizygous or homozygous deletion of CDKN2C had a worse OS compared with cases that were intact at this region (22 months versus 38 months; P = 0.003). Using gene mapping we identified three homozygous deletions at 1p32.3, containing CDKN2C, all of which lacked expression of CDKN2C. Cases with homozygous deletions of CDKN2C were the most proliferative myelomas, defined by an expression-based proliferation index, consistent with its biological function as a cyclin-dependent kinase inhibitor. CONCLUSIONS: Our results suggest that deletions of CDKN2C are important in the progression and clinical outcome of myeloma.
Authors: Peter Liebisch; Andreas Viardot; Nicole Bassermann; Christiane Wendl; Katrin Roth; Hartmut Goldschmidt; Hermann Einsele; Christian Straka; Stephan Stilgenbauer; Hartmut Döhner; Martin Bentz Journal: Br J Haematol Date: 2003-07 Impact factor: 6.998
Authors: Norma C Gutiérrez; Juan L García; Jesús M Hernández; Eva Lumbreras; Mariana Castellanos; Ana Rasillo; Gema Mateo; José M Hernández; Sonia Pérez; Alberto Orfao; Jesús F San Miguel Journal: Blood Date: 2004-07-06 Impact factor: 22.113
Authors: T Tasaka; J Berenson; R Vescio; T Hirama; C W Miller; M Nagai; J Takahara; H P Koeffler Journal: Br J Haematol Date: 1997-01 Impact factor: 6.998
Authors: Friedrich W Cremer; Jelena Bila; Isabelle Buck; Mutlu Kartal; Dirk Hose; Carina Ittrich; Axel Benner; Marc S Raab; Ann-Cathrin Theil; Marion Moos; Hartmut Goldschmidt; Claus R Bartram; Anna Jauch Journal: Genes Chromosomes Cancer Date: 2005-10 Impact factor: 5.006
Authors: S Wuilleme; N Robillard; L Lodé; F Magrangeas; H Beris; J-L Harousseau; J Proffitt; S Minvielle; H Avet-Loiseau Journal: Leukemia Date: 2005-02 Impact factor: 11.528
Authors: C S Debes-Marun; G W Dewald; S Bryant; E Picken; R Santana-Dávila; N González-Paz; J M Winkler; R A Kyle; M A Gertz; T E Witzig; A Dispenzieri; M Q Lacy; S V Rajkumar; J A Lust; P R Greipp; R Fonseca Journal: Leukemia Date: 2003-02 Impact factor: 11.528
Authors: Abel Sánchez-Aguilera; Julio Delgado; Francisca I Camacho; Margarita Sánchez-Beato; Lydia Sánchez; Carlos Montalbán; Manuel F Fresno; Carmen Martín; Miguel A Piris; Juan F García Journal: Blood Date: 2003-11-26 Impact factor: 22.113
Authors: F Li; L Hu; Y Xu; Z Li; S Yi; Z Gu; C Li; M Hao; K Ru; F Zhan; A Zetterberg; W Yuan; T Cheng; L Qiu Journal: Leukemia Date: 2015-09-16 Impact factor: 11.528
Authors: Angela Baker; Esteban Braggio; Susanna Jacobus; Sungwon Jung; Dirk Larson; Terry Therneau; Angela Dispenzieri; Scott A Van Wier; Gregory Ahmann; Joan Levy; Louise Perkins; Seungchan Kim; Kimberly Henderson; David Vesole; S Vincent Rajkumar; Diane F Jelinek; John Carpten; Rafael Fonseca Journal: Blood Date: 2013-02-19 Impact factor: 22.113
Authors: Laura Chiecchio; Gian Paolo Dagrada; Rebecca K M Protheroe; David M Stockley; Alastair G Smith; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross Journal: Haematologica Date: 2009-05-19 Impact factor: 9.941